Metraipolis › archive › dc_7538bb7e27f7

Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials — Europe PMC PMID:41206930

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41206930
DOI
10.1093/jnci/djaf326
License (as archived)
solo-consultazione
Archived
2026-11-05T11:20:46.752Z
SHA-256 of the archived text
7b879acd40cb6eef0af6b39a0746b603e23d42ed38fad7392c541bb9ec1087d3
Stable URL of this page
https://metraipolis.com/documento/dc_7538bb7e27f7

How to cite

Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials — Europe PMC PMID:41206930 — Europe PMC (en), https://europepmc.org/article/MED/41206930 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7538bb7e27f7 (Metraipolis archive dc_7538bb7e27f7, sha256 7b879acd40cb6eef0af6b39a0746b603e23d42ed38fad7392c541bb9ec1087d3)
BibTeX
@misc{dc7538bb7e27f7,
  title = {Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials — Europe PMC PMID:41206930},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41206930},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7538bb7e27f7; sha256 7b879acd40cb6eef0af6b39a0746b603e23d42ed38fad7392c541bb9ec1087d3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41206930. Agents can read the archived copy with the MCP tool read_document.